ijms-logo

Journal Browser

Journal Browser

Molecular Underpinnings of Schizophrenia Spectrum Disorders, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 855

Special Issue Editors


E-Mail Website
Guest Editor
Department of Neuroscience, University of Turin, 10125 Turin, Italy
Interests: psychiatric research; schizophrenia; neuroscience; mental health; schizophrenia spectrum disorders
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Via Cherasco, 13, 10126 Turin, Italy
Interests: schizophrenia; psychoses; neuroimaging; omic sicence; mental health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Schizophrenia spectrum disorders have a lifetime prevalence of 0.5–1% and remain among the top 15 causes of years lived with disability worldwide. They strongly affect the functioning and quality of life of patients and their loved ones. The difficulties resulting from these disorders also generate economic problems in the form of considerable direct and, mainly, indirect costs. The molecular alterations underlying schizophrenia and related disorders are only partially understood. Therefore, studying the molecular biology of this group of psychiatric conditions is of great scientific interest. In particular, the disorder encompasses various symptoms and lies at the interface between neurodevelopment and neuroprogression processes affecting the central nervous system (CNS). Omics sciences and artificial intelligence are revolutionizing the way we approach the biology of complex biological systems such as the CNS and its disorders. Applying these methods to patients with schizophrenia spectrum disorders might provide exciting insights into their pathophysiology, clarify the relationship between specific molecular findings and various symptom domains, and open new avenues for identifying possible new molecular targets.

We invite researchers in this field to submit original research articles or reviews that describe and discuss the most recent advances and developments in the molecular underpinnings of schizophrenia spectrum disorders.

Potential topics include, but are not limited to, the following:

  • Genetic or genomic studies on schizophrenia spectrum disorders;
  • Epigenetic or transcriptomic studies on schizophrenia spectrum disorders;
  • Proteomic and metabolomic studies on schizophrenia spectrum disorders;
  • Molecular studies on schizophrenia applying deep learning techniques;
  • Studies that correlate the symptoms or cognitive characteristics of schizophrenia spectrum disorders with molecular aspects.

Prof. Dr. Paola Rocca
Dr. Claudio Brasso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • schizophrenia spectrum disorders
  • central nervous system (CNS)
  • psychotic disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

36 pages, 1854 KB  
Review
Molecular Signatures of Schizophrenia and Insights into Potential Biological Convergence
by Malak Saada and Shani Stern
Int. J. Mol. Sci. 2025, 26(19), 9830; https://doi.org/10.3390/ijms26199830 - 9 Oct 2025
Viewed by 747
Abstract
Schizophrenia is a highly polygenic and clinically heterogeneous disorder. In this paper, we first review layer-specific evidence across genetics, epigenetics, transcriptomics, proteomics, and patient-derived induced pluripotent stem cell (iPSC) models, then integrate cross-layer findings. Genetics research identifies widespread risk architecture. Hundreds of loci [...] Read more.
Schizophrenia is a highly polygenic and clinically heterogeneous disorder. In this paper, we first review layer-specific evidence across genetics, epigenetics, transcriptomics, proteomics, and patient-derived induced pluripotent stem cell (iPSC) models, then integrate cross-layer findings. Genetics research identifies widespread risk architecture. Hundreds of loci from common, rare, and CNV analyses. Epigenetics reveals disease-associated DNA methylation and histone-mark changes. These occur at neuronally active enhancers and promoters, together with chromatin contacts that link non-coding risk to target genes. Transcriptomics show broad differential expression, isoform-level dysregulation, and disrupted co-expression modules. These alterations span synaptic signaling, mitochondrial bioenergetics, and immune programs. Proteomics demonstrates coordinated decreases in postsynaptic scaffold and mitochondrial respiratory-chain proteins in cortex, with complementary inflammatory signatures in serum/plasma. iPSC models recapitulate disease-relevant phenotypes: including fewer synaptic puncta and excitatory postsynaptic currents, electrophysiological immaturity, oxidative stress, and progenitor vulnerability. These same models show partial rescue under targeted perturbations. Integration across layers highlights convergent pathways repeatedly supported by ≥3 independent data types: synaptic signaling, immune/complement regulation, mitochondrial/energetic function, neurodevelopmental programs and cell-adhesion complexes. Within these axes, several cross-layer convergence genes/proteins (e.g., DLG4/PSD-95, C4A, RELN, NRXN1/NLGN1, OXPHOS subunits, POU3F2/BRN2, PTN) recur across cohorts and modalities. Framing results through cross-layer and shared-pathway convergence organizes heterogeneous evidence and prioritizes targets for mechanistic dissection, biomarker development, and translational follow-up. Full article
Show Figures

Figure 1

Back to TopTop